๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

AG-120 clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 3 trials in our Ireland, UK, USA and China registers that name AG-120 as an intervention. Synced 25 Sep 2026
3Current trials
0Recruiting now
3Lead sponsors
4Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards
At a glance

AG-120 is named as an intervention in 3 current clinical trials in our Ireland, UK, USA and China registers. None are recruiting at the moment. The most common phase is Phase 3. The sponsor with the most trials is Stichting Hemato-Oncologie voor Volwassenen Nederland (1). The most-studied condition is Leukemia, Myeloid, Acute.

Trials by status

  • Active, closed3100%

Trials by phase

  • Phase 3267%
  • Phase 1/2133%
01

Clinical trials of AG-120

3 trials
StudyPhaseStatusLead sponsorRegisters
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248 · ClinicalTrials.gov ↗ · Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS)
Phase 3 Active, closed Institut de Recherches Internationales Servier China
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
NCT03839771 · Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
Phase 3 Active, closed Stichting Hemato-Oncologie voor Volwassenen Nederland Ireland
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
NCT02677922 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute
Phase 1/2 Active, closed Celgene UK, USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with AG-120

6 conditions
Leukemia, Myeloid, Acute2Acute Myeloid Leukemia1Myelodysplastic Syndrome With Excess Blasts-21Newly Diagnosed Acute Myeloid Leukemia (AML)1Untreated AML1AML Arising From Myelodysplastic Syndrome (MDS)1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Stichting Hemato-Oncologie voor Volwassenen Nederland1
Celgene1
Institut de Recherches Internationales Servier1
04

By country register

RegisterTrialsRecruiting
Clinical trials in Ireland10
Clinical trials in UK10
Clinical trials in USA10
Clinical trials in China10

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about AG-120 trials

How many clinical trials are testing AG-120?

3 current trials in our Ireland, UK, USA and China registers name AG-120 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are AG-120 trials recruiting patients?

Not at the moment. None of the 3 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.

Who sponsors AG-120 clinical trials?

Stichting Hemato-Oncologie voor Volwassenen Nederland (1), Celgene (1) and Institut de Recherches Internationales Servier (1). The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how AG-120 works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how AG-120 works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists AG-120 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.